Braun Stacey Associates Inc Biomarin Pharmaceutical Inc Transaction History

Braun Stacey Associates Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 21, 2023	SELL	$85.07 - $94.48 $15.1 Million - $16.8 Million	-177,727 Reduced 94.8%	9,750 $863,000
Q2 2023 Jul 28, 2023	SELL	$86.68 - $100.3 $16.8 Million - $19.4 Million	-193,853 Reduced 50.84%	187,477 $16.3 Million
Q1 2023 May 08, 2023	BUY	$87.74 - $117.27 $15 Million - $20.1 Million	171,529 Added 81.76%	381,330 $37.1 Million
Q4 2022 Feb 07, 2023	BUY	$80.93 - $108.63 $3.15 Million - $4.22 Million	38,883 Added 22.75%	209,801 $21.7 Million
Q3 2022 Nov 08, 2022	BUY	$82.16 - $96.94 $14 Million - $16.6 Million	170,918 New	170,918 $14.5 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Braun Stacey Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Braun Stacey Associates Inc with notifications on news.